PTAB Mulls Validity Of Novartis Syringe IP In Regeneron Fight
The Patent Trial and Appeal Board on Thursday considered whether Novartis can beat an invalidity challenge from Regeneron over a pre-filled eye injection syringe patent with an argument that skilled artisans...To view the full article, register now.
Already a subscriber? Click here to view full article